stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Free cash flow margin
ImmunityBio, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was −173.8%, up 98.8 percentage points from fiscal 2025 (−272.6%). Over the past ten years it has ranged from −185,766.7% (fiscal 2017) to −272.6% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −272.6% | 2,427.50 |
| FY2024 | −2,700.1% | 61,181.13 |
| FY2023 | −63,881.2% | 118,160.48 |
| FY2022 | −182,041.7% | (151,261.80) |
| FY2021 | −30,779.9% | (2,119.87) |
| FY2020 | −28,660.0% | (21,566.63) |
| FY2019 | −7,093.4% | 154,759.82 |
| FY2018 | −161,853.2% | 23,913.48 |
| FY2017 | −185,766.7% | (83,146.22) |
| FY2016 | −102,620.5% | (90,948.42) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 66.0% |
| PTGX Protagonist Therapeutics, Inc. compare | 46.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.00% |
| TGTX TG Therapeutics, Inc. compare | 2.17% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.8% |
| TWST Twist Bioscience Corporation compare | −22.2% |
| IBRX ImmunityBio, Inc. | −173.8% |
| CYTK Cytokinetics, Incorporated compare | −519.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement